Total antibody positive (No.) | Underlying disease (No.) | IgA + (%) | IgM + (%) | IgG + (%) | Nabs + (%) |
---|---|---|---|---|---|
Baseline | |||||
 Symptomatic (65) | Yes (23) | 5 (21.74%) | 0 (0.00%) | 23 (100.00%) | 14 (60.87%) |
No (42) | 7 (16.67%) | 3 (7.14%) | 42 (100.00%) | 24 (57.14%) | |
 Asymptomatic (248) | Yes (74) | 17 (22.97%) | 7 (9.46%) | 74 (100.00%) | 29 (39.19%) |
No (174) | 36 (20.69%) | 23 (13.22%) | 174 (100.00%) | 68 (39.08%) | |
First follow-up | |||||
 Symptomatic (56) | Yes (20) | 3 (15.00%) | 0 (0.00%) | 20 (100.00%) | 15 (75.00%) |
No (36) | 3 (8.33%) | 1 (2.78%) | 36 (100.00%) | 22 (61.11%) | |
 Asymptomatic (156) | Yes (46) | 8 (17.39%) | 1 (2.17%) | 46 (100.00%) | 20 (43.48%) |
No (110) | 13 (11.82%) | 3 (2.73%) | 109 (99.09%) | 45 (40.91%) | |
Second follow-up | |||||
 Symptomatic (60) | Yes (20) | 0 (0.00%) | 0 (0.00%) | 19 (95.00%) | 13 (65.00%) |
No (40) | 0 (0.00%) | 0 (0.00%) | 39 (97.50%) | 27 (67.50%) | |
 Asymptomatic (178) | Yes (48) | 6 (12.50%) | 1 (2.08%) | 44 (91.67%) | 23 (47.92%) |
No (130) | 11 (8.46%) | 3 (2.31%) | 129(99.23%) | 61(46.92%) |